Biocryst Pharmaceuticals Inc (BCRX) concluded trading on Thursday at a closing price of $8.22, with 3.31 million shares of worth about $27.18 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 9.31% during that period and on April 24, 2025 the price saw a gain of about 3.27%. Currently the company’s common shares owned by public are about 208.54M shares, out of which, 197.24M shares are available for trading.
Stock saw a price change of 13.85% in past 5 days and over the past one month there was a price change of 1.86%. Year-to-date (YTD), BCRX shares are showing a performance of 9.31% which increased to 86.39% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $4.03 but also hit the highest price of $9.50 during that period. The average intraday trading volume for Biocryst Pharmaceuticals Inc shares is 3.45 million. The stock is currently trading 12.70% above its 20-day simple moving average (SMA20), while that difference is up 4.63% for SMA50 and it goes to 6.31% higher than SMA200.
Biocryst Pharmaceuticals Inc (NASDAQ: BCRX) currently have 208.54M outstanding shares and institutions hold larger chunk of about 78.48% of that.
The stock has a current market capitalization of $1.72B and its 3Y-monthly beta is at 1.06. It has posted earnings per share of -$0.43 in the same period. It has Quick Ratio of 2.58. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for BCRX, volatility over the week remained 5.12% while standing at 5.88% over the month.
Stock’s fiscal year EPS is expected to rise by 82.03% while it is estimated to increase by 380.01% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Wedbush on February 25, 2025 offering an Outperform rating for the stock and assigned a target price of $15 to it. Coverage by JP Morgan stated Biocryst Pharmaceuticals Inc (BCRX) stock as an Overweight in their note to investors on November 20, 2023, suggesting a price target of $10 for the stock. On September 18, 2023, RBC Capital Mkts Upgrade their recommendations, while on August 04, 2023, Jefferies Upgrade their ratings for the stock with a price target of $11. Stock get a Buy rating from BofA Securities on July 13, 2023.
